Growing market potential for safer chemicals

Safer chemicals are good for business, creating jobs and growth

safer-chemicals-report
A major US-based study has found that producing and using safer chemicals is good for business, and recommends that companies that are not already evaluating the potential of safer chemicals should do so. The study estimates that the market for safer chemicals has 24 times the growth potential of the worldwide conventional chemicals market , and that job creation in safer goods and services is well ahead of the conventional chemical industry.

A new US report finds significant market growth potential for safer, less toxic chemicals. The report from Trucost, an independent research firm, builds a strong case for the growing market potential for safer chemicals based on an in depth examination of economic research, market trends, and interviews with business across the value chain. The research was commissioned by the Green Chemistry & Commerce Council (CG3) and the American Sustainable Business Council (ASBC).

The report entitled, Making the Business & Economic Case for Safer Chemistry, evaluates the potential business and economic value of safer chemistry. This includes reducing the use and generation of hazardous substances, reducing the human health and environmental impacts of processes and products, and creating safer products. The research included interviews with 17 industry experts, as well as a review of literature and available data on the business and economic opportunities achievable through safer chemistry and the business and economic value at risk from not adopting safer chemistry.

Report Key Findings:

  • The market for safer chemicals is estimated to have 24 times the growth of conventional chemicals market worldwide, from 2011 to 2020.
  • A growing market demand for safer ingredients across various products, including personal care, cleaning products, baby products, apparel and footwear, healthcare, electronics, building materials and furnishings.
  • Potential financial costs of conventional chemistry, including regulatory fines, loss of access to markets, and social costs of accidents and incidents are driving the market for safer alternatives.
  • Job growth in safer goods and services is well ahead of conventional chemical industry.
Sources and more information
  • New US report shows growing market potential for safer chemicals,
    trucost, 06 May 2015.
  • Safer chemicals are good for business, creating jobs and growth,
    chemtrust, JULY 28, 2015.

Labeling Kids with Bogus ‘Mental Disorders’

Childhood is Not a Mental Disorder

Video published on 20 Dec 2010 by CCHRInt.

More information
  • 20 Million Kids & Adolescents are labeled with “mental disorders” that are based solely on a checklist of behaviors. There are no brain scans, x-rays, genetic or blood tests that can prove they are “mentally ill“, yet these children are stigmatized for life with psychiatric disorders, and prescribed dangerous,life-threatening psychiatric drugs. The statistics on children being drugged in the United States, by IMS health are 8.4 million including 1 million children between the ages of 0-5.
  • More about ADHD & Child Mental Disorders and about the Number of Children & Adolescents Taking Psychiatric Drugs in the U.S.
  • Watch more pharma videos on @DES_Journal YouTube channel.

Assisted reproductive technology industry boom in India: government regulation is critically needed

Donor Deaths in India Highlight Surrogacy Perils

image of egg-and-stones
Two women have died from causes tied to their role as egg donors in India’s booming market for artificial reproduction. Advocates are pressing the government to publicize health warnings and pass regulations. Egg and stones  Ylva Staberg.

The tragic death of the young woman in the prime of her life is shocking, Sudha Sundararaman, vice president of the All India Democratic Women’s Association, told Women’s eNews in a phone interview. While there are laws in the country to prevent the sale of blood, there are no binding guidelines for such procedures related to assisted reproductive technology. With no monitoring of their impact on the health of women, most clinics just do as they please.

Continue reading Donor Deaths in India Highlight Surrogacy Perils,
WomensEnews, Swapna Majumdar, June 17, 2014.

The Full Blue Moon 16th #FullMoonEngageMe #SocialMedia Event on #EmpireAvenue #SocialNetworking

July 29, 2015, join our free social media event taking place at each Full Moon.

blue-moon
Between Wednesday 29th of July and Sunday 2nd of August 2015, join our free social media event taking place at each Full Moon – via #EAv – and give a boost to your social networking! Nearly Full Blue Moon image via peter jones.

The Full Blue Moon

Each year, the moon completes its final cycle about 11 days before the Earth finishes its orbit around the sun. These days add up, and every two and a half years or so, there is an extra full moon, called a Blue Moon. The origin of the term is uncertain, and its precise definition has changed over the years. The term is commonly used today to describe the second full moon of a calendar month, but it was originally the name given to the third full moon of a season containing four full moons..

16th #FullMoonEngageMe Schedule

Our free event will start on Wednesday the 29th of July 2015 at +/- 07:00 UTC and will last until Sunday the 2nd of August at +/- 24:00 in HERE.

What is this about?

Our 1st #FullMoonEngageMe event launched in May 2014… Grab a unique opportunity to super charge your social networking by meeting and connecting with top social media engagers on Empire Avenue and beyond. Time for some “serious buzz” and serious FUN!

Confused?

See you soon 😉

Psychopathology and social functioning in men prenatally exposed to diethylstilbestrol

Previous research has suggested increased psychopathology in prenatally DES-exposed persons

Split-of-Personality image
In this 1993 study, DES-exposed men had almost twice the prevalence of at least one episode of MDD and had significantly more recurrent episodes. Split of Personality image by Derrick Tyson.

1993 Study Abstract

Previous research has suggested increased psychopathology in prenatally diethylstibestrol (DES)-exposed persons. The current study compares the psychiatric histories and social functioning of 27 men with a history of high-dose prenatal DES exposure and their unexposed brothers. We expected DES subjects to show greater lifetime psychopathology and poorer social functioning than controls. Both groups showed high rates of lifetime depression, lifetime alcoholism, and current psychiatric symptoms in excess of community norms. The only diagnosis on which DES subjects exceeded their unexposed brothers was Major Depressive Disorder (MDD). DES-exposed men had almost twice the prevalence of at least one episode of MDD and had significantly more recurrent episodes. The relatively small number of subjects with concomitant lack of statistical power may have contributed to the difficulty obtaining significant effects.

Sources and more information
  • Psychopathology and social functioning in men prenatally exposed to diethylstilbestrol, Pillard RC, Rosen LR, Meyer-Bahlburg H, Weinrich JD, Feldman JF, Gruen R, Ehrhardt AA., Psychosom Med. 1993 Nov-Dec;55(6):485-91, NCBI PMID: 8310108, 1993.
More DES DiEthylStilbestrol Resources

Recurrent ovarian cancer: gene therapy may improve patients survival

AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer

ovarian-cancer image
Use of gene therapy to deliver a protein that suppresses the development of female reproductive organs may improve the survival of patients with ovarian cancer that has recurred after chemotherapy, which happens 70 percent of the time and is invariably fatal. Ovarian cancer image via MedicalXpress

2015 Study Abstract

To improve ovarian cancer patient survival, effective treatments addressing chemoresistant recurrences are particularly needed. Mullerian inhibiting substance (MIS) has been shown to inhibit the growth of a stem-like population of ovarian cancer cells. We have recently engineered peptide modifications to human MIS [albumin leader Q425R MIS (LRMIS)] that increase production and potency in vitro and in vivo. To test this novel therapeutic peptide, serous malignant ascites from highly resistant recurrent ovarian cancer patients were isolated and amplified to create low-passage primary cell lines. Purified recombinant LRMIS protein successfully inhibited the growth of cancer spheroids in vitro in a panel of primary cell lines in four of six patients tested. Adeno-associated virus (AAV) -delivered gene therapy has undergone a clinical resurgence with a good safety profile and sustained gene expression. Therefore, AAV9 was used as a single i.p. injection to deliver LRMIS to test its efficacy in inhibiting growth of palpable tumors in patient-derived ovarian cancer xenografts from ascites (PDXa). AAV9-LRMIS monotherapy resulted in elevated and sustained blood concentrations of MIS, which significantly inhibited the growth of three of five lethal chemoresistant serous adenocarcinoma PDXa models without signs of measurable or overt toxicity. Finally, we tested the frequency of MIS type II receptor expression in a tissue microarray of serous ovarian tumors by immunohistochemistry and found that 88% of patients bear tumors that express the receptor. Taken together, these preclinical data suggest that AAV9-LRMIS provides a potentially well-tolerated and effective treatment strategy poised for testing in patients with chemoresistant serous ovarian cancer.

Sources and more information
  • AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer, PNAS, doi: 10.1073/pnas.1510604112, July 27, 2015.
  • Gene therapy may improve survival of patients with recurrent ovarian cancer, MedicalXpress, July 27, 2015.

When Drug Manufacturers delay Disclosure of Serious and Unexpected Adverse Events to the FDA

Some adverse drug events not reported by manufacturers to FDA by 15-day mark

image of drugs
About 10 percent of serious and unexpected adverse events are not reported by drug manufacturers to the U.S. Food and Drug Administration under the 15-day timeframe set out in federal regulations, according to an article published online by JAMA Internal Medicine. Drugs image by Rennett Stowe.

2015 Study Abstract

This study investigates patient and event characteristics associated with manufacturers’ delayed submission of expedited adverse event reports to the US Food and Drug Administration.

Federal regulations define adverse drug events as those “associated with the use of a drug in humans whether or not considered drug related”. Health care professionals and consumers can voluntarily report adverse drug events directly to the US Food and Drug Administration (FDA) or the drug manufacturer. Serious adverse events (AEs) are defined by the regulation as those involving “death, a life-threatening adverse drug experience, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect.” Unexpected AEs are defined as those involving “any adverse drug experience that is not listed in the current labeling for the drug product.” Serious and unexpected events are classified as expedited, and manufacturers receiving any such reports are mandated to forward them to the FDA “as soon as possible but in no case later than 15 calendar days of the initial receipt of the information.” The regulation also requests that the manufacturer conduct an investigation and forward findings as follow-up reports to the FDA. Previous studies highlighted that reports by manufacturers to the FDA of serious adverse drug events have increased steadily during the past decade. Manufacturer compliance with the regulation to report serious and unexpected AEs to the FDA within 15 calendar days is unknown, although some media coverage has offered anecdotal examples of delays. As the FDA uses this information to update drug warnings, delays in reporting can have important public health consequences, particularly if manufacturers selectively delay reporting based on relevant patient outcomes. We investigated patient and event characteristics associated with manufacturers’ delayed submission of the expedited reports to the FDA.

Sources and more information
  • Some adverse drug events not reported by manufacturers to FDA by 15-day mark, MedicalXpress, July 27, 2015.
  • Drug Manufacturers’ Delayed Disclosure of Serious and Unexpected Adverse Events to the US Food and Drug Administration, JAMA Internal Medicine,  doi:10.1001/jamainternmed.2015.3565, July 27, 2015.

The Mobile Health Industry is Booming, Infographic

The use of modern technologies for health-related applications is on the rise

Mobile-health-industry
The Mobile and Wearable Sensor Industry Projections, Mobile Health Sensor Abilities, Function of Current Mobile Health Sensors, Benefits of Mobile Health Sensors, Future Innovations.

The use of modern technologies for health-related applications is on the rise. The continued miniaturization of components and reduced manufacturing costs are helping to push mobile health into the mainstream. Indeed, the industry is projected to grow by leaps and bounds in the coming years.

Sources and more information

Association between fetal DES-exposure and psychiatric disorders in adolescence/adulthood

Psychiatric disorders evidence from a French cohort of 1002 prenatally DES-exposed children

identity-disorder image
HHORAGES Association work demonstrates that prenatal exposure to DES is associated with a high risk of psychiatric disorders in adolescence and adulthood. Image by JustCallMe_♥Bethy♥.

2015 Study Abstract

In utero diethylstibestrol (DES) exposure has been demonstrated to be associated with somatic abnormalities in adult men and women. Conversely, the data are contradictory regarding the association with psychological or psychiatric disorders during adolescence and adulthood. This work was designed to determine whether prenatal exposure to DES affects brain development and whether it is associated with psychiatric disorders in male and female adolescents and young adults.

HHORAGES Association, a national patient support group, has assembled a cohort of 1280 women who took DES during pregnancy. We obtained questionnaire responses from 529 families, corresponding to 1182 children divided into three groups:

  1. Group 1 (n = 180): firstborn children without DES treatment,
  2. Group 2 (n = 740): exposed children,
  3. and Group 3 (n = 262): children born after a previous pregnancy treated by DES.

No psychiatric disorders were reported in Group 1. In Group 2, the incidence of disorders was drastically elevated (83.8%), and in Group 3, the incidence was still elevated (6.1%) compared with the general population. This work demonstrates that prenatal exposure to DES is associated with a high risk of psychiatric disorders in adolescence and adulthood.

Sources and more information
  • Association between fetal DES-exposure and psychiatric disorders in adolescence/adulthood: evidence from a French cohort of 1002 prenatally exposed children, Soyer-Gobillard MO, Paris F, Gaspari L, Courtet P, Sultan C., NCBI PMID: 26172930, 2015.
More DES DiEthylStilbestrol Resources

Medicine side effects reporting app

Download the Yellow Card smartphone app here

yellow-card-app
Fifty years on from its inception, the Yellow Card Scheme is moving into the digital age through a free-access mobile app launched 14 July by Life Sciences Minister, Mr George Freeman MP. This is the only health app that allows patients, carers and healthcare professionals to report medicine side effects directly to the Yellow Card Scheme.

The Yellow Card is a free smartphone app for reporting suspected side effects (or adverse drug reactions) to the UK’s Yellow Card Scheme. Created in collaboration with the Medicines and Healthcare products Regulatory Agency (MHRA), the UK government medicines watchdog, the Yellow Card Smartphone App is the only health app that allows you to report medicine side effects directly to the Yellow Card Scheme to help the MHRA ensure they are acceptably safe for patients. Users can select specific medicines or vaccines to track and receive news and alerts about them.

Yellow Card Smartphone App Key Features

  • provide a convenient alternative to using paper Yellow Card forms or the Yellow Card website
  • the app is free to use for everyone on iOS and Android
  • is easy to use for reporting side effects directly to the Yellow Card Scheme
  • enables users to:
    • create a ‘watch list’ of medications to receive official news and alerts on
    • view numbers of Yellow Cards received by MHRA for medicines of interest
    • see immediate response that shows Yellow Card has been accepted
    • submit updates to Yellow Cards already submitted
    • view previous Yellow Cards submitted through the app
Mick Foy, Group Manager for MHRA’s Vigilance and Risk Management of medicines division said:

The contribution of patients, careers and healthcare professionals alike in reporting suspected side effects to the Yellow Card Scheme is vital. The evidence helps MHRA detect safety issues and take the necessary action to keep the public safe.

Moving Yellow Card onto a mobile app is a logical progression in this digital age, allowing us to build on the existing website to improve user engagement.
It offers some good functionality to access further safety information, and it will continue to evolve over the course of the WEB-RADR project based on user feedback. “

Life Sciences Minister George Freeman MP commented:

The Yellow Card Scheme has played a vital role in the safety of medicines for the last 50 years and the launch of this new mobile app brings it into the 21st century.

By making the scheme accessible to researchers, healthcare professionals and millions of patients, it will not only improve the safety of reporting but ultimately better protect people’s health and support research in the NHS. “

More info and videos
  • Download the free app on iTunes and GooglePlay to easily report drug side effects directly to the Yellow Card Scheme via your cell phone or tablet.
  • Digital evolution for ground-breaking Yellow Card Scheme,
    GOV.UK press release, 14 July 2015.